載入中
NASDAQHealthcareBiotechnology
最新資料
US$1.91
+US$0.02 · +1.06%
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
前收盤價
US$1.91
+US$0.02 · +1.06%
盤中時間採用ET。市場資料可能有所延遲。
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
日內區間
目前US$1.91
52週區間
目前US$1.91
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
44
合理估值
情緒
54
多空交錯
風險
65
高風險
動能
31
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
日內區間
目前US$1.91
52週區間
目前US$1.91
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 35.97萬 USD | 40.1萬 USD | 14.58萬 USD | 11.98萬 USD | 4.6萬 USD |
| 銷貨成本 | 2.38萬 USD | 2.81萬 USD | — | — | — |
| 毛利 | 33.59萬 USD | 37.29萬 USD | 14.58萬 USD | 11.98萬 USD | 4.6萬 USD |
| 研究與開發 | 1009.47萬 USD | 534.87萬 USD | 403.46萬 USD | 351.34萬 USD | 72.91萬 USD |
| 銷售、一般及管理費用 | 588.83萬 USD | 657.94萬 USD | 1133.2萬 USD | 1558.05萬 USD | 2562.48萬 USD |
| 營業費用 | 1598.3萬 USD | 1192.81萬 USD | 1536.66萬 USD | 1898.33萬 USD | 2635.39萬 USD |
| 利息收入 | 26.62萬 USD | 61.61萬 USD | 55.23萬 USD | 1.17萬 USD | — |
| 利息支出 | — | — | — | — | 181.54萬 USD |
| 折舊和攤銷 | 21萬 USD | 18.91萬 USD | 16.57萬 USD | 12.05萬 USD | 8.91萬 USD |
| 營業利益 | −1564.71萬 USD | −1155.52萬 USD | −1522.08萬 USD | −1886.35萬 USD | −2630.79萬 USD |
| 淨利 | −1424.2萬 USD | −897.94萬 USD | −1041.77萬 USD | −1322.23萬 USD | −4430.33萬 USD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
評級樣本有限，僅3項
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年9月8日 | 1:20 | — | — |
股票分割 | 2021年10月27日 | 1:4,000 | — | — |
股票分割 | 2015年7月7日 | 1:20 | — | — |
股票分割 | 2013年4月15日 | 1:50 | — | — |
股票分割 | 2008年3月3日 | 1:250 | — | — |
已生效 2026年9月8日
1:20
已生效 2021年10月27日
1:4,000
已生效 2015年7月7日
1:20
已生效 2013年4月15日
1:50
已生效 2008年3月3日
1:250
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
